Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

Purpose: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain. We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2007-08, Vol.13 (16), p.4874-4881
Hauptverfasser:	Guo, Tianhua, Agaram, Narasimhan P, Wong, Grace C, Hom, Glory, D'Adamo, David, Maki, Robert G, Schwartz, Gary K, Veach, Darren, Clarkson, Bayard D, Singer, Samuel, DeMatteo, Ronald P, Besmer, Peter, Antonescu, Cristina R
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Apoptosis - drug effects Benzamides Benzenesulfonates - pharmacology Cell Proliferation - drug effects Dasatinib Drug Resistance, Neoplasm Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - genetics GIST Humans imatinib Imatinib Mesylate kinase inhibition Mice Mutation Niacinamide - analogs & derivatives nilotinib Phenylurea Compounds Phosphorylation Piperazines - pharmacology Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins c-kit - genetics Pyridines - pharmacology Pyrimidines - pharmacology receptor tyrosine kinase resistance Sorafenib Thiazoles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!